Login to Your Account



Myriad Ruling: Just BRCA Genes or Underpinnings of Biotech?

By Donna Young


Wednesday, March 31, 2010
If upheld on appeal, a federal district judge's ruling Monday that invalidated patent claims related to the BRCA1 and BRCA2 genes held by Salt Lake City-based Myriad Genetics Inc. and the University of Utah Research Foundation could have far-reaching implications for gene patenting and the future of biotechnology product development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription